Bulk drugs export momentum which is based on low-price competition has slowed down last year. Export volumes of 40% of the varieties in China decline. The industry believes that, bulk drugs exports basing on low-price competition can not be sustained. The increasing cost pressures, the external economic environment and the increasing uncertainty about the prospects of bulk drugs exports make the situation worse.

Industry of pharmaceutical raw materials is currently facing more challenges than opportunities. Searching for an international market expansion, with the varieties of raw material drug companies to break through the pressing problems of the sustainable development advantages. Turned to the high value-added varieties, turned to the new needs of the market, to further enhance the environmental technology, will be one of the trends in raw material drug production enterprise transformation. The fermentation glutathione and fermented semi-synthesis of orlistat and other varieties of market potential worth the wait.

In 2011, Chinese exports of bulk drugs in the shadow of the debt crisis in Europe and America under a certain pressure. 2011 focuses on tracking 75 chemical raw materials and formulations, bulk drugs exports fell 5%, compared with a year earlier. 65 focus on tracking the varieties of chemical raw materials exports, about 40% of the varieties of export volume has declined. Export geographical, exports to Asia rose steadily, the average export price over the previous year growth of about 6%; exports to Europe continued to decline, down 9.5%, but the average price increased by 12.5%; the basic price of exports to North America flat with last year; the whole of the increase in exports of South America out of the downward parabola, but the price is up 23%; the highest increase in exports to Africa reached 9.6%, the average price increase of 5.5%.

It is noteworthy that vitamin C, penicillin and other exclusive advantages of bulk drugs, but because the capacity is too high or excessive competition caused by the decline in export prices or shrinking turnover. At the same time, however, heparin sodium exclusive, resource-based pharmaceutical raw materials prices continued to rise, the raw material drug companies need to turn to new market demands.

Erythromycin thiocyanate greatly favorable for the era of high prices, has a high content of impurity generation erythromycin base of the synthesis of the downstream product quality and stability advantage of market opportunities more worthy of attention. This is mainly because the U.S. and European companies of the second generation macrocyclic lactone of the process line is erythromycin base for raw materials. Erythromycin base in the case of high sulfur red prices, this can both drugs and raw materials as the generation of erythromycin, but also can be used in the old second-generation macrocyclic lactone intermediate varieties, their opportunities in turnning around should be noted.

At the same time, pharmaceutical raw materials manufacturers should strive to tap suitable for expansion into international markets, with the advantages of sustainable development of new varieties. According to past experience, large-scale basis for bulk drugs, can easily cause pollution or high energy consumption products is not appropriate to introduce some small scale, involving fewer varieties of competitive enterprise. The market is small in the Chinese market. But for the variety which has international market, it is worth considering.

Market potential of Fermentation glutathione is promising. Chinese glutathione companies began the production and export. And the Chinese market is relatively weak. So the finish product mainly depends on the international market. So international importers need to buy glutathione from China. Although there are fewer Chinese manufacturers and the scales are small, there is a larger opportunity for market.

Some clinical applications are replaced by new varieties. They have small scales of production and marketing. There are low profits in production process and there are few manufacturers. So the prospects of these species do not seem bright. But because there is still a gap between demand and supply, there are opportunities for variety. Some old varieties are also being developed for new uses. They will play their value once again and will bring new market opportunities for manufacturers.

Source:http://www.cospcn.com